Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Practice Changing Data at ASCO26
LIBRETTO-432 Adjuvant selpercatinib vs placebo:
- HR 0.172 (p=0.0003)
- 24-mo EFS: 91.5% vs 61.1%
- Consistent across ALL subgroups
This is why we Test Every patient. Every. Single. One.”
Other articles featuring Narjust Florez on OncoDaily.